

NOVOGEN LIMITED
(ASX: NRT)



ASX RELEASE
5 MAY 2014

Novogen Presentation at Cavendish Global Impact Forum Available Online

Novogen to present its unique approach to cancer and degenerative diseases therapy to international forum at United Nations in New York

SYDNEY, May 5, 2014 - Novogen Limited (ASX: NRT; NASDAQ: NVGN) an oncology drug development company is presenting today at the Cavendish Global Impact Forum at the United Nations Headquarters in New York. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.

Novogen is one of 43 companies selected globally to present over the 3-day forum.

The presentation plus the larger corporate hand-out have been posted on the Company's website.

Dr Graham Kelly, Novogen CEO, said today, "The Novogen story has been some time in the making, but in the last 12 months has finally taken shape, thanks to some key technological breakthroughs by the Company's very skilled and hard-working scientists. It's this exciting chapter of the Novogen story that I am presenting later today in New York."

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States (NYC, May 2014), Europe (London, October 2014) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015).

About Novogen

Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer, ovarian cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing an intra-peritoneal product for late-stage ovarian cancer.

Further information on Novogen is available on the Company's website, www.novogen.com

Further information on Cavendish Global is available at <http://cavendishglobal.com>

Contact

In Australia


Dr Douglas Pretsell
Instinctif Partners
+61 (0)3 9657 0706

In the USA

David Carey
Lazar Partners
+ 1 212-867-1762
Novogen@lazarpartners.com

In ROW

Sue Charles/Stefanie Bacher
Instinctif Partners
+44 (0)20 7457 2020



NOVOGEN